Results of chemotherapy in advanced carcinoma of the fallopian tube.
Forty-six patients with measurable disease received chemotherapy for advanced primary or recurrent carcinoma of the fallopian tube. The response rate was 9% with single-agent therapy, 29% with multiagent therapy without cisplatin, and 81% with cisplatin-containing combination therapy. Survival was significantly improved in Stage III/IV with the addition of cisplatin-based combination therapy.
Peters
W A
WA
Puget Sound Oncology Consortium, Seattle, WA.
Andersen
W A
WA
Hopkins
M P
MP
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging
D000970:Antineoplastic Agents; D002699:Chlorambucil; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin